The Department for Health and Social Care has asked NICE to conduct an appraisal of Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma.
Following on from information received from the company the timelines for this appraisal have been revised and this appraisal is now anticipated to begin during late-November 2021 when we will write to you about how you can get involved.